{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:48Z","timestamp":1791474708143,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is the most common type of primary malignant brain tumor, characterized by a poor prognosis, high recurrence rate, and elevated mortality. In recent years, gene-targeted therapies leveraging small molecule compounds have gained momentum as a promising avenue for GBM intervention. Myoferlin (MYOF), a type II membrane protein of the Ferlin family, has emerged as a key regulator of membrane dynamics\u2014governing processes such as vesicular trafficking, endocytosis, and membrane repair. In this study, we explore the previously uncharted role of MYOF in GBM progression and its potential as a diagnostic and therapeutic target. Our data reveal that silencing MYOF markedly suppresses glioma growth both in vitro and in vivo. Mechanistically, MYOF knockdown disrupts the nuclear translocation of phosphorylated STAT3 (P-STAT3), a critical oncogenic signaling event. Notably, we identified Entacapone (ENT), a small molecule capable of targeting MYOF, which significantly impedes glioma development across experimental models. These findings position MYOF as a novel molecular lever in GBM pathogenesis and highlight ENT as a potential therapeutic agent that exerts anti-glioma effects by blocking MYOF-mediated P-STAT3 nuclear import.<\/jats:p>","DOI":"10.1038\/s41420-026-03254-0","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:03:56Z","timestamp":1784041436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5865-2456","authenticated-orcid":false,"given":"Peiqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3660-0924","authenticated-orcid":false,"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2110-2278","authenticated-orcid":false,"given":"Zhenqiu","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2778-3955","authenticated-orcid":false,"given":"Kankai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-1927","authenticated-orcid":false,"given":"Qichuan","family":"Zhuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9416-1195","authenticated-orcid":false,"given":"Jianjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"3254_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41582-019-0220-2","volume":"15","author":"AM Molinaro","year":"2019","unstructured":"Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15:405\u201317.","journal-title":"Nat Rev Neurol"},{"key":"3254_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"3254_CR3","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neuro Oncol. 2020;22:iv1\u2013iv96.","journal-title":"Neuro Oncol"},{"key":"3254_CR4","first-page":"299","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70:299\u2013312.","journal-title":"CA Cancer J Clin"},{"key":"3254_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jamaoncol.2022.2844","volume":"8","author":"TR Berger","year":"2022","unstructured":"Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review. JAMA Oncol. 2022;8:1493\u2013501.","journal-title":"JAMA Oncol"},{"key":"3254_CR6","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","volume":"186","author":"F Winkler","year":"2023","unstructured":"Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, et al. Cancer neuroscience: state of the field, emerging directions. Cell. 2023;186:1689\u2013707.","journal-title":"Cell"},{"key":"3254_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/neuonc\/noab271","volume":"24","author":"EA Chiocca","year":"2022","unstructured":"Chiocca EA, Gelb AB, Chen CC, Rao G, Reardon DA, Wen PY, et al. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. Neuro Oncol. 2022;24:951\u201363.","journal-title":"Neuro Oncol"},{"key":"3254_CR8","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.7150\/thno.41498","volume":"10","author":"L Tong","year":"2020","unstructured":"Tong L, Li J, Li Q, Wang X, Medikonda R, Zhao T, et al. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics. 2020;10:5943\u201356.","journal-title":"Theranostics"},{"key":"3254_CR9","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.7150\/thno.26754","volume":"8","author":"N Hovhannisyan","year":"2018","unstructured":"Hovhannisyan N, Fillesoye F, Guillouet S, Ibazizene M, Toutain J, Gourand F, et al. [18F] Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: comparative analysis with [18F] FDG in human xenograft models. Theranostics. 2018;8:4563\u201373.","journal-title":"Theranostics"},{"key":"3254_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molmed.2024.02.004","volume":"30","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ali H, Khan F, Pang L, Chen P. Epigenetic regulation of tumor-immune symbiosis in glioma. Trends Mol Med. 2024;30:429\u201342.","journal-title":"Trends Mol Med"},{"key":"3254_CR11","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1038\/s44318-025-00463-8","volume":"44","author":"C Cretu","year":"2025","unstructured":"Cretu C, Chernev A, Kib\u00e9di Szab\u00f3 CZ, Pena V, Urlaub H, Moser T, et al. Structural insights into lipid membrane binding by human ferlins. EMBO J. 2025;44:3926\u201358.","journal-title":"EMBO J"},{"key":"3254_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nature01573","volume":"423","author":"D Bansal","year":"2003","unstructured":"Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423:168\u201372.","journal-title":"Nature"},{"key":"3254_CR13","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1038\/s41388-019-1135-5","volume":"39","author":"T Qian","year":"2020","unstructured":"Qian T, Liu C, Ding Y, Guo C, Cai R, Wang X, et al. PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis. Oncogene. 2020;39:2069\u201387.","journal-title":"Oncogene"},{"key":"3254_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06179-0","volume":"9","author":"T Zhang","year":"2018","unstructured":"Zhang T, Li J, He Y, Yang F, Hao Y, Jin W, et al. A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nat Commun. 2018;9:3726.","journal-title":"Nat Commun"},{"key":"3254_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41556-021-00644-7","volume":"23","author":"S Gupta","year":"2021","unstructured":"Gupta S, Yano J, Mercier V, Htwe HH, Shin HR, Rademaker G, et al. Lysosomal retargeting of Myoferlin mitigates membrane stress to enable pancreatic cancer growth. Nat Cell Biol. 2021;23:232\u201342.","journal-title":"Nat Cell Biol"},{"key":"3254_CR16","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-13-1142","volume":"73","author":"A Turtoi","year":"2013","unstructured":"Turtoi A, Blomme A, Bellahc\u00e8ne A, Gilles C, Hennequi\u00e8re V, Peixoto P, et al. Myoferlin is a key regulator of EGFR activity in breast cancer. Cancer Res. 2013;73:5438\u201348.","journal-title":"Cancer Res"},{"key":"3254_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1126\/science.1171721","volume":"324","author":"DJ Gough","year":"2009","unstructured":"Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009;324:1713\u20136.","journal-title":"Science"},{"key":"3254_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41388-019-0996-y","volume":"39","author":"M Qian","year":"2020","unstructured":"Qian M, Wang S, Guo X, Wang J, Zhang Z, Qiu W, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-\u03baB pathways. Oncogene. 2020;39:428\u201342.","journal-title":"Oncogene"},{"key":"3254_CR19","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s41418-025-01494-8","volume":"32","author":"Y Tu","year":"2025","unstructured":"Tu Y, Xu L, Fu G, Wang J, Xia P, Tao Z, et al. Lactylation-driven USP4-mediated ANXA2 stabilization and activation promotes maintenance and radioresistance of glioblastoma stem cells. Cell Death Differ. 2025;32:1648\u201363.","journal-title":"Cell Death Differ"},{"key":"3254_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","volume":"39","author":"T Hara","year":"2021","unstructured":"Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2021;39:779\u201392.","journal-title":"Cancer Cell"},{"key":"3254_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","volume":"38","author":"R Siersb\u00e6k","year":"2020","unstructured":"Siersb\u00e6k R, Scabia V, Nagarajan S, Chernukhin I, Papachristou EK, Broome R, et al. IL6\/STAT3 signaling hijacks estrogen receptor \u03b1 enhancers to drive breast cancer metastasis. Cancer Cell. 2020;38:412\u201323.","journal-title":"Cancer Cell"},{"key":"3254_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/15548627.2016.1178446","volume":"12","author":"H Xue","year":"2016","unstructured":"Xue H, Yuan G, Guo X, Liu Q, Zhang J, Gao X, et al. A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway. Autophagy. 2016;12:1129\u201352.","journal-title":"Autophagy"},{"key":"3254_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","volume":"23","author":"E Kim","year":"2013","unstructured":"Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23:839\u201352.","journal-title":"Cancer Cell"},{"key":"3254_CR24","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/cancers11121888","volume":"11","author":"HW Liu","year":"2019","unstructured":"Liu HW, Lee PM, Bamodu OA, Su YK, Fong IH, Yeh CT, et al. Enhanced Hsa-miR-181d\/p-STAT3 and Hsa-miR-181d\/p-STAT5A ratios mediate the anticancer effect of garcinol in STAT3\/5A-addicted glioblastoma. Cancers. 2019;11:1888.","journal-title":"Cancers"},{"key":"3254_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell. 2019;36:498\u2013511.","journal-title":"Cancer Cell"},{"key":"3254_CR26","doi-asserted-by":"publisher","first-page":"20252","DOI":"10.1074\/jbc.M802306200","volume":"283","author":"KR Doherty","year":"2008","unstructured":"Doherty KR, Demonbreun AR, Wallace GQ, Cave A, Posey AD, Heretis K, et al. The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J Biol Chem. 2008;283:20252\u201360.","journal-title":"J Biol Chem"},{"key":"3254_CR27","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.7150\/ijbs.74304","volume":"18","author":"X Wu","year":"2022","unstructured":"Wu X, Wei S, Chen M, Li J, Wei Y, Zhang J, et al. P2RY13 exacerbates intestinal inflammation by damaging the intestinal mucosal barrier via activating IL-6\/STAT3 pathway. Int J Biol Sci. 2022;18:5056\u201369.","journal-title":"Int J Biol Sci"},{"key":"3254_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","volume":"15","author":"S Grivennikov","year":"2009","unstructured":"Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103\u201313.","journal-title":"Cancer Cell"},{"key":"3254_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.chembiol.2021.02.012","volume":"28","author":"S Ziegler","year":"2021","unstructured":"Ziegler S, Sievers S, Waldmann H. Morphological profiling of small molecules. Cell Chem Biol. 2021;28:300\u201319.","journal-title":"Cell Chem Biol"},{"key":"3254_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ccell.2025.02.003","volume":"43","author":"S M\u00fcller","year":"2025","unstructured":"M\u00fcller S, Sanfelice D, Workman P. Probing cancer with small-molecule tools\u2014progress and challenges. Cancer Cell. 2025;43:323\u20137.","journal-title":"Cancer Cell"},{"key":"3254_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41589-021-00920-5","volume":"18","author":"AR Conery","year":"2022","unstructured":"Conery AR, Rocnik JL, Trojer P. Small molecule targeting of chromatin writers in cancer. Nat Chem Biol. 2022;18:124\u201333.","journal-title":"Nat Chem Biol"},{"key":"3254_CR32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","volume":"21","author":"R Offringa","year":"2022","unstructured":"Offringa R, K\u00f6tzner L, Huck B, Urbahns K. The expanding role for small molecules in immuno-oncology. Nat Rev Drug Discov. 2022;21:821\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"3254_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cell.2019.05.028","volume":"178","author":"JL Wojtaszek","year":"2019","unstructured":"Wojtaszek JL, Chatterjee N, Najeeb J, Ramos A, Lee M, Bian K, et al. A small molecule targeting mutagenic translesion synthesis improves chemotherapy. Cell. 2019;178:152\u20139.","journal-title":"Cell"},{"key":"3254_CR34","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2015.05.023","volume":"161","author":"SL Schreiber","year":"2015","unstructured":"Schreiber SL, Kotz JD, Li M, Aub\u00e9 J, Austin CP, Reed JC, et al. Advancing biological understanding and therapeutics discovery with small-molecule probes. Cell. 2015;161:1252\u201365.","journal-title":"Cell"},{"key":"3254_CR35","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.molcel.2025.04.026","volume":"85","author":"E Lagan","year":"2025","unstructured":"Lagan E, Gannon D, Silva AJ, Bibawi P, Doherty AM, Nimmo D, et al. A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma. Mol Cell. 2025;85:2110\u201327.","journal-title":"Mol Cell"},{"key":"3254_CR36","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/neuonc\/noae277","volume":"27","author":"C Riviere-Cazaux","year":"2025","unstructured":"Riviere-Cazaux C, Graser CJ, Warrington AE, Hoplin MD, Andersen KM, Malik N, et al. A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery. Neuro Oncol. 2025;27:948\u201362.","journal-title":"Neuro Oncol"},{"key":"3254_CR37","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/neuonc\/not025","volume":"15","author":"M Priester","year":"2013","unstructured":"Priester M, Copanaki E, Vafaizadeh V, Hensel S, Bernreuther C, Glatzel M, et al. STAT3 silencing inhibits glioma single-cell infiltration and tumor growth. Neuro Oncol. 2013;15:840\u201352.","journal-title":"Neuro Oncol"},{"key":"3254_CR38","doi-asserted-by":"crossref","unstructured":"Hung CY, Kang EY, Jacek K, Yu C, Zhang X, Zhu Y, et al. Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade. Neuro Oncol. 2025; noaf099.","DOI":"10.1093\/neuonc\/noaf099"},{"key":"3254_CR39","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1039\/D1BM01723C","volume":"10","author":"SF Liang","year":"2022","unstructured":"Liang SF, Zuo FF, Yin BC, Ye BC. Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3. Biomater Sci. 2022;10:1582\u201390.","journal-title":"Biomater Sci"},{"key":"3254_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/15548627.2015.1017192","volume":"11","author":"L You","year":"2015","unstructured":"You L, Wang Z, Li H, Shou J, Jing Z, Xie J, et al. The role of STAT3 in autophagy. Autophagy. 2015;11:729\u201339.","journal-title":"Autophagy"},{"key":"3254_CR41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s13238-010-0078-y","volume":"1","author":"Z Huang","year":"2010","unstructured":"Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell. 2010;1:638\u201355.","journal-title":"Protein Cell"},{"key":"3254_CR42","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/neuonc\/noac093","volume":"24","author":"L Zhang","year":"2022","unstructured":"Zhang L, Nesvick CL, Day CA, Choi J, Lu VM, Peterson T, et al. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma. Neuro Oncol. 2022;24:1700\u201311.","journal-title":"Neuro Oncol"},{"key":"3254_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/cdd.2016.110","volume":"24","author":"Y Shi","year":"2017","unstructured":"Shi Y, Zhou W, Cheng L, Chen C, Huang Z, Fang X, et al. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells. Cell Death Differ. 2017;24:167\u201380.","journal-title":"Cell Death Differ"},{"key":"3254_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41586-025-08997-x","volume":"643","author":"C Faust Akl","year":"2025","unstructured":"Faust Akl C, Andersen BM, Li Z, Giovannoni F, Diebold M, Sanmarco LM, et al. Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025;643:219\u201329.","journal-title":"Nature"},{"key":"3254_CR45","doi-asserted-by":"publisher","first-page":"8228","DOI":"10.1158\/1078-0432.CCR-08-1329","volume":"14","author":"M Abou-Ghazal","year":"2008","unstructured":"Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008;14:8228\u201335.","journal-title":"Clin Cancer Res"},{"key":"3254_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05717-z","volume":"14","author":"Y Shou","year":"2023","unstructured":"Shou Y, Yue C, Wang Q, Liu J, Xu J, Miao Q, et al. circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM\/IL-6\/STAT3 pathway. Cell Death Dis. 2023;14:232.","journal-title":"Cell Death Dis"},{"key":"3254_CR47","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41586-024-07387-z","volume":"629","author":"N Diaz","year":"2024","unstructured":"Diaz N, Perez C, Escribano AM, Sanz G, Priego J, Lafuente C, et al. Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. Nature. 2024;629:945\u201350.","journal-title":"Nature"},{"key":"3254_CR48","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1021\/jacs.4c11930","volume":"147","author":"Y Liu","year":"2025","unstructured":"Liu Y, Sun X, Liu Q, Han C, Rao Y. A dual-target and dual-mechanism design strategy by combining inhibition and degradation together. J Am Chem Soc. 2025;147:3110\u20138.","journal-title":"J Am Chem Soc"},{"key":"3254_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-025-02017-9","author":"J Ouyang","year":"2025","unstructured":"Ouyang J, Chen J, Wu Z, You K, Chen T, Gao YQ, et al. Navigating condensate micropolarity to enhance small-molecule drug targeting. Nat Chem Biol. 2025. https:\/\/doi.org\/10.1038\/s41589-025-02017-9.","journal-title":"Nat Chem Biol"},{"key":"3254_CR50","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1089\/hgtb.2017.086","volume":"28","author":"AP Manceur","year":"2017","unstructured":"Manceur AP, Kim H, Misic V, Andreev N, Dorion-Thibaudeau J, Lanthier S, et al. Scalable lentiviral vector production using stable HEK293SF producer cell lines. Hum Gene Ther Methods. 2017;28:330\u20139.","journal-title":"Hum Gene Ther Methods"},{"key":"3254_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-4939-1785-3_19","volume":"1235","author":"S Seidel","year":"2015","unstructured":"Seidel S, Garvalov BK, Acker T. Isolation and culture of primary glioblastoma cells from human tumor specimens. Methods Mol Biol. 2015;1235:263\u201375.","journal-title":"Methods Mol Biol"},{"key":"3254_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah6816","volume":"10","author":"Y Shi","year":"2018","unstructured":"Shi Y, Guryanova OA, Zhou W, Liu C, Huang Z, Fang X, et al. Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. Sci Transl Med. 2018;10:eaah6816.","journal-title":"Sci Transl Med"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03254-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:16Z","timestamp":1791471736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03254-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3254"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03254-0","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Approved procedures were followed for patient recruitment and after receiving written informed consent from each patient, tissues samples were collected. The First Affiliated Hospital of Wenzhou Medical University Ethics Committee approved all related experiments (KY2021-R129).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"409"}}